A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Abroad (travel likely)RecruitingPHASE3
Conditions
High Risk Smoldering Multiple Myeloma (HR-SMM)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Emory University - Winship Cancer Institute, Atlanta, Georgia, United States
Dana Farber / Harvard Cancer Center, Boston, Massachusetts, United States
Study leads
Clinical Trial Management
Study Director
Regeneron Pharmaceuticals